NEWS
Institutional Subscription: Comprehensive Analyses to Enhance Your Global and Local Impact
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Henrik Agersí¸
Novo Nordisk A S - Bagsvaerd / Denmark
Others
AD Scientific Index ID: 4433053
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Henrik Agersí¸'s MOST POPULAR ARTICLES
1-)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administrationLB Knudsen, PF Nielsen, PO Huusfeldt, NL Johansen, K Madsen, ...Journal of medicinal chemistry 43 (9), 1664-1669, 20009182000
2-)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menH Agersø, LB Jensen, B Elbrønd, P Rolan, M ZdravkovicDiabetologia 45, 195-202, 20026302002
3-)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjectsT Vilsbøll, H Agersø, T Krarup, JJ HolstThe Journal of Clinical Endocrinology & Metabolism 88 (1), 220-224, 20035642003
4-)
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjectsB Elbrønd, G Jakobsen, S Larsen, H Agersø, LB Jensen, P Rolan, J Sturis, ...Diabetes care 25 (8), 1398-1404, 20023762002
5-)
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetesCB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, J Veldhuis, ...Diabetes 51 (2), 424-429, 20023722002
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept